<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673138</url>
  </required_header>
  <id_info>
    <org_study_id>1508016333</org_study_id>
    <secondary_id>1K12DK094714-01</secondary_id>
    <nct_id>NCT02673138</nct_id>
  </id_info>
  <brief_title>Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion</brief_title>
  <official_title>Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, cross-over study as subjects will be studied under both
      study conditions - suspension of subcutaneous insulin infusion via pump during treatment with
      insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with
      insulin and canagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 4 visits: an enrollment/screening visit, a control visit with pump
      suspension prior to treatment with canagliflozin, a visit with pump suspension while on
      canagliflozin and an end of study visit. Each of the pump suspension visits will be
      approximately 20-hour overnight admissions to the Hospital Research Unit (HRU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</measure>
    <time_frame>20 hours</time_frame>
    <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</measure>
    <time_frame>20 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</measure>
    <time_frame>20 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</measure>
    <time_frame>20 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Basal interruption</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal interruption with canagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canagliflozin</intervention_name>
    <description>basal interruption with canagliflozin</description>
    <arm_group_label>Basal interruption with canagliflozin</arm_group_label>
    <other_name>Invokana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>basal interruption without canagliflozin</intervention_name>
    <description>basal interruption</description>
    <arm_group_label>Basal interruption</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-45 years

          2. Clinical diagnosis of T1D (type 1 diabetes) (formal antibody and/or genetic testing
             will not be required)

          3. Duration of T1D ≥ 1 year

          4. HbA1c ≤ 9 %

          5. Treated with continuous subcutaneous insulin infusion (with or without adjunctive
             treatment with a SGLT2 inhibitor) for at least 3 months

          6. Body weight &gt; 40 kg

          7. Be in good general health without other acute or chronic illness that in the judgment
             of the investigator could interfere with the study or jeopardize subject safety

          8. Normal hematocrit

          9. Able to give consent

         10. Female subjects of reproductive potential must be abstinent or consistently using
             appropriate family planning methods.

        Exclusion Criteria:

          1. Insulin resistant (defined as requiring &gt; 1.5 units/kg/day at time of study
             enrollment)

          2. Renal impairment, determined as eGFR &lt; 60 ml/minute/1.73m2

               1. History of unstable or rapidly progressing renal disease

               2. Conditions of congenital renal glucosuria

               3. Renal allograft

               4. Recurrent UTI (urinary tract infection)

               5. History of Vesico-ureteral-reflux disease

          3. Presence of any medical or psychiatric disorder that may interfere with subject safety
             or study conduct

          4. Use of metformin, thiazolidinedione or GLP1 agonist within 1 month prior to screening
             visit. For those subjects on canagliflozin or other SGLT2 inhibitors, an alternate
             study procedure may be utilized as described above

          5. Use of any medications (besides insulin or SGLT2 inhibitor) known to effect blood
             glucose levels, including oral or other systemic glucocorticoid therapy. Inhaled,
             intranasal, or rectal corticosteroid use is allowed as long as not given within 2
             weeks of the closed loop admissions. Use of topical glucocorticoids is allowable as
             long as affected skin area does not overlap with study device sites

          6. History of hypoglycemic seizure within last 3 months

          7. History of diabetic ketoacidosis (DKA) requiring medical intervention (ie. emergency
             room visit and/or hospitalization) within 1 month prior to the screening visit

          8. Allergies or contraindication to the contents of canagliflozin tablets or insulin

          9. Volume depleted subjects. Subjects at risk for volume depletion due to co-existing
             conditions or concomitant medications, such as loop diuretics who cannot carefully
             monitor their volume status should be excluded from the study

         10. Female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy

         11. Recurrent GU (genitourinary) infections

         12. Uncircumcised males secondary to increased risk of development of GU infections

         13. History of hypotension, defined as blood pressure (BP) &lt;10th% for age and sex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Patel, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Basal Interruption With or Without Canagliflozin</title>
          <description>Subjects will undergo basal interruption with or without canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basal Interruption With or Without Canagliflozin</title>
          <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</title>
        <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</title>
          <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197" spread="24"/>
                    <measurement group_id="O2" value="99" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.1"/>
                    <measurement group_id="O2" value="0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="5"/>
                    <measurement group_id="O2" value="36" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Basal Interruption</title>
          <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
basal interruption without canagliflozin: basal interruption</description>
        </group>
        <group group_id="E2">
          <title>Basal Interruption With Canagliflozin</title>
          <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neha S. Patel, DO</name_or_title>
      <organization>Yale Pediatric Diabetes</organization>
      <phone>203-764-6747</phone>
      <email>neha.patel@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

